This study will determine the efficacy and toxicity of 4 cy-cles of neoadjuvant docetaxel chemotherapy given every 3 weeks in conjunction with subcutaneous trastuzumab (Herceptin SC) followed by 1 year of subcutaneous tras-tuzumab in Nigerian women with HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.